A COVID-19 vaccine trial on humans has begun in the United
Kingdom.
The vaccine is developed by a team of researchers from the
Imperial College, London and this is the first time it will be tested on
humans.
The first volunteer has received a small dose of the vaccine
and is said to be in stable condition while under close monitoring at a
facility in West London.
On how the vaccine works against COVID-19, it will “train
the body’s immune system to recognise the virus and help it to defend itself
against a future attack” using “bits of genetic code (called self-amplifying
RNA), rather than bits of the virus”.
“The aim of the vaccine is to trick the body into thinking
it has already seen the virus and made an immune response, so when you come
into contact with it in real life, you should already be immune.”
A first dose will also be administered to several other
people over the next few days, while the second dose will be given within one
month.
A total of 300 people have volunteered to participate in the
trial in the initial phase.
The research team is led by Robin Shattock, a professor at
Imperial College.
“The first participant marks an important step for our saRNA
vaccine platform, which has never before been trialled in humans,” Shattock is
quoted as saying in an article on the trial process on the college’s website.
“We now eagerly await rapid recruitment to the trial so that
we can assess both the safety of the vaccine and its ability to produce
neutralising antibodies which would indicate an effective response against
COVID-19. I look forward to our progress in the coming months.”
The development of the vaccine has received more than £41
million in funding from the UK government and another £5 million in donations
by philanthropists.
Speaking on the vaccine, Katrina Pollock of the department
of infectious disease and chief investigator of the study, said: “We have
reached a significant milestone in this ground-breaking study with the first
dose of a self-amplifying RNA vaccine delivered safely.
“We are now poised to test the vaccine in the dose
evaluation phase before moving forward to evaluating it in larger numbers.”
The UK Medical Research Council, UK Research and Innovation,
the Department of Health and Social Care, the Department for Business, Energy
and Industrial Strategy, the National Institute for Health Research, among
others have supported the research effort.
“This astonishingly fast vaccine development – compared to
the years it normally takes – is a result of the remarkably hard and
collaborative work of the scientists, trialists and regulators,” Fiona Watt,
professor and executive chair of the medical research council, said.
“These human trials will contribute to global efforts to
find a vaccine, which is our best hope for preventing COVID-19 and enabling
life to return to normal.”
Imperial College, through VacEquity Global Health (VGH),
will partner with Morningside Ventures, on rapid development and distribution
of the vaccine within and outside the UK.
As of June 23, 2020, more than 300,000 persons have tested
positive for COVID-19 in the UK, out of which over 42,000 deaths have been
recorded.
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com